Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi:: Report from SENTRY Antimicrobial Surveillance Program, 2000

被引:315
作者
Pfaller, MA
Messer, SA
Hollis, RJ
Jones, RN
机构
[1] Univ Iowa, Coll Med, Dept Pathol, Div Med Microbiol, Iowa City, IA 52242 USA
[2] JMI Labs, JONES Grp, North Liberty, IA USA
关键词
D O I
10.1128/AAC.46.4.1032-1037.2002
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Posaconazole, ravuconazole, and voriconazole are new triazole derivatives that possess potent, broad-spectrum antifungal activity. We evaluated the in vitro activity of these investigational triazoles compared with that of itraconazole and amphotericin B against 239 clinical isolates of filamentous fungi from the SENTRY Program, including Aspergillus spp. (198 isolates), Fusarium spp. (7 isolates), Penicillium spp. (19 isolates), Rhizopus spp. (4 isolates), Mucor spp. (2 isolates), and miscellaneous species (9 isolates). The isolates were obtained from 16 different medical centers in the United States and Canada between January and December 2000. In vitro susceptibility testing was performed using the microdilution broth method outlined in the National Committee for Clinical Laboratory Standards M38-P document. Overall, posaconazole was the most active compound, inhibiting 94% of isolates at a MIC of less than or equal to1 mug/ml, followed by voriconazole (91%), amphotericin B (89%), ravuconazole (88%), and itraconazole (70%). All three new triazoles demonstrated excellent activity (MIC, less than or equal to1 mug/ml) against Aspergillus spp. (114 Aspergillus fumigatus, 22 Aspergillus niger, 13 Aspergillus flavus, 9 Aspergillus versicolor, 8 Aspergillus terreus, and 32 Aspergillus spp.): posaconazole (98%), voriconazole (98%), ravuconazole (92%), amphotericin B (89%), and itraconazole (72%). None of the triazoles were active against Fusarium spp. (MIC at which 50% of the isolates tested were inhibited [MIC50], >8 mug/ml) or Mucor spp. (MIC50, >8 mug/ml). Posaconazole and ravuconazole were more active than voriconazole against Rhizopus spp. (MIC50, 1 to 2 mug/ml versus >8 mug/ml, respectively). Based on these results, all three new triazoles exhibited promising activity against Aspergillus spp. and other less commonly encountered isolates of filamentous fungi. The clinical value of these in vitro data remains to be seen, and in vitro-in vivo correlation is needed for both new and established antifungal agents. Surveillance efforts should be expanded in order to monitor the spectrum of filamentous fungal pathogens and their in vitro susceptibility as these new antifungal agents are introduced into clinical use.
引用
收藏
页码:1032 / 1037
页数:6
相关论文
共 39 条
[1]   Trends in antifungal drug susceptibility of Cryptococcus neoformans isolates in the United States:: 1992 to 1994 and 1996 to 1998 [J].
Brandt, ME ;
Pfaller, MA ;
Hajjeh, RA ;
Hamill, RJ ;
Pappas, PG ;
Reingold, AL ;
Rimland, D ;
Warnock, DW .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (11) :3065-3069
[2]   In vitro and in vivo activities of SCH 56592 (posaconazole), a new triazole antifungal agent, against Aspergillus and Candida [J].
Cacciapuoti, A ;
Loebenberg, D ;
Corcoran, E ;
Menzel, F ;
Moss, EL ;
Norris, C ;
Michalski, M ;
Raynor, K ;
Halpern, J ;
Mendrick, C ;
Arnold, B ;
Antonacci, B ;
Parmegiani, R ;
Yarosh-Tomaine, T ;
Miller, GH ;
Hare, RS .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (08) :2017-2022
[3]   Role of early diagnosis and aggressive surgery in the management of invasive pulmonary aspergillosis in neutropenic patients [J].
Caillot, D ;
Mannone, L ;
Cuisenier, B ;
Couaillier, JF .
CLINICAL MICROBIOLOGY AND INFECTION, 2001, 7 :54-61
[4]   Burden of aspergillosis-related hospitalizations in the United States [J].
Dasbach, EJ ;
Davies, GM ;
Teutsch, SM .
CLINICAL INFECTIOUS DISEASES, 2000, 31 (06) :1524-1528
[5]   An EORTC multicentre prospective survey of invasive aspergillosis in haematological patients: Diagnosis and therapeutic outcome [J].
Denning, DW ;
Marinus, A ;
Cohen, J ;
Spence, D ;
Herbrecht, R ;
Pagano, L ;
Kibbler, C ;
Kcrmery, V ;
Offner, F ;
Cordonnier, C ;
Jehn, U ;
Ellis, M ;
Collette, L ;
Sylvester, R .
JOURNAL OF INFECTION, 1998, 37 (02) :173-180
[6]   In vitro activities of BMS-207147 against over 600 contemporary clinical bloodstream isolates of Candida species from the SENTRY antimicrobial surveillance program in North America and Latin America [J].
Diekema, DJ ;
Pfaller, MA ;
Messer, SA ;
Houston, A ;
Hollis, RJ ;
Doern, GV ;
Jones, RN .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (09) :2236-2239
[7]   Introduction to antifungal drugs [J].
Dismukes, WE .
CLINICAL INFECTIOUS DISEASES, 2000, 30 (04) :653-657
[8]   Optimal susceptibility testing conditions for detection of azole resistance in Aspergillus spp.:: NCCLS collaborative evaluation [J].
Espinel-Ingroff, A ;
Bartlett, M ;
Chaturvedi, V ;
Ghannoum, M ;
Hazen, KC ;
Pfaller, MA ;
Rinaldi, M ;
Walsh, TJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (06) :1828-1835
[9]   In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi [J].
Espinel-Ingroff, A .
JOURNAL OF CLINICAL MICROBIOLOGY, 2001, 39 (03) :954-958
[10]   Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts [J].
Espinel-Ingroff, A .
JOURNAL OF CLINICAL MICROBIOLOGY, 1998, 36 (10) :2950-2956